amyotroph
later
sclerosi
al
fatal
neurodegen
diseas
character
progress
upper
lower
motor
neuron
degener
al
highli
heterogen
disord
phenotyp
variabl
involv
number
clinic
aspect
site
onset
age
onset
rate
progress
nonmotor
involv
respons
therapi
beghi
et
al
make
difficult
deciph
pathogenesi
develop
therapeut
strategi
also
biomark
reflect
heterogen
may
use
stratif
miss
combin
genet
environmentalexogen
modifi
factor
believ
underli
variabl
identif
pathway
affect
modifi
factor
great
interest
may
target
therapeut
intervent
age
known
risk
factor
al
major
al
patient
diseas
onset
year
age
howev
patient
age
onset
year
year
exist
repres
respect
patient
recent
report
larg
multicent
italian
studi
calvo
et
al
sever
factor
genet
environmentalexogen
report
modifi
age
onset
patient
anim
model
al
fu
mutat
frequent
associ
earlyonset
diseas
famili
sporad
case
et
al
et
al
earlier
onset
al
also
observ
soldier
profession
soccer
player
haley
et
al
pupillo
et
al
patient
anticip
onset
might
link
heavi
physic
exercis
repeat
trauma
andor
exposur
yet
unknown
toxic
agent
genet
predispos
individu
beghi
morrison
pupillo
et
al
beghi
mutant
mous
model
al
genet
background
earlier
age
onset
mous
model
genet
background
despit
equal
express
mutant
protein
marino
et
al
mice
also
faster
diseas
progress
intrins
mark
downregul
specif
pathway
involv
mitochondri
function
protein
qualiti
control
nardo
et
al
marino
et
al
convers
polymorph
lower
express
correl
delay
age
onset
al
patient
li
et
al
van
hoeck
et
al
moreov
mutant
mice
femal
show
later
onset
male
delay
increas
exercis
veldink
et
al
summar
differ
combin
intrins
exogen
factor
hardli
discern
may
lead
anticip
delay
onset
diseas
want
test
whether
modifi
factor
converg
common
pathogen
pathway
lead
either
earli
late
diseas
onset
would
impli
identif
phenotyp
biomark
distinguish
two
popul
al
patient
relev
pathway
consid
therapeut
intervent
toward
aim
signific
cohort
incid
al
patient
either
earli
year
age
late
year
age
diseas
onset
recruit
populationbas
italian
registri
sever
analys
perform
found
epigenet
rearrang
wholeblood
dna
methyl
could
distinguish
two
group
al
patient
tremolizzo
et
al
howev
differ
plasma
amino
acid
level
observ
relat
age
onset
cecchi
et
al
work
identifi
protein
phenotyp
biomark
peripher
blood
mononuclear
cell
pbmc
cohort
patient
indic
protein
level
pbmc
could
good
biolog
correl
age
onset
al
phenotyp
biomark
also
analyz
two
mutant
mous
model
al
earli
late
diseas
onset
indic
common
chang
sporad
form
biomark
protein
involv
mainten
protein
homeostasi
proteostasi
proteostasi
attain
sever
qualitycontrol
system
assist
protein
fold
clear
misfold
protein
respond
protein
aggreg
whose
major
player
molecular
chaperon
interestingli
impair
proteostasi
emerg
key
contributor
pathogenesi
al
ruegsegg
saxena
antibodi
western
dot
blot
use
human
mous
sampl
rabbit
polyclon
antipeptidylprolyl
cistran
isomeras
ppia
antibodi
dilut
millipor
rabbit
polyclon
antiheat
shock
protein
hsp
dilut
stressgen
rabbit
polyclon
kda
glucoseregul
protein
dilut
santa
cruz
biotechnolog
inc
mous
monoclon
antiendoplasm
reticulum
protein
dilut
stressgen
rabbit
monoclon
antiprotein
deglycas
dilut
abcam
mous
monoclon
antiheat
shock
cognat
kda
protein
dilut
santa
cruz
biotechnolog
inc
rabbit
polyclon
dilut
proteintech
goat
antimous
antirabbit
peroxidaseconjug
secondari
antibodi
santa
cruz
biotechnolog
inc
follow
approv
protocol
ethic
committe
comitato
etico
interaziendal
aou
san
giovanni
battista
di
torino
ao
cto
maria
adelaid
di
torino
torino
itali
comitato
etico
degli
spedali
civili
di
brescia
brescia
itali
comitato
etico
provincial
di
modena
modena
itali
written
inform
consent
obtain
particip
subject
patient
enrol
three
italian
populationbas
registri
lombardia
piemont
emilia
romagna
newli
diagnos
definit
probabl
possibl
al
accord
el
escori
criteria
brook
elig
patient
year
age
earli
al
year
age
late
al
diagnosi
control
resid
sex
agematch
year
randomli
chosen
within
hospit
patient
among
subject
admit
surgeri
nonspontan
evolv
diseas
subject
enrol
discoveri
phase
studi
earli
al
late
al
control
earli
late
control
demograph
clinic
characterist
describ
tabl
subject
enrol
valid
studi
al
patient
control
demograph
clinic
characterist
describ
tabl
case
sporad
wide
although
partial
screen
alscaus
mutat
perform
tremolizzo
et
al
two
earli
al
case
carri
tardp
mutat
one
late
al
case
carri
mutat
anoth
one
optn
mutat
procedur
involv
anim
care
approv
institut
anim
care
use
committe
conduct
conform
follow
law
regul
polici
govern
care
use
laboratori
anim
italian
govern
law
dlg
authoris
issu
march
ministri
health
mario
negri
institut
regul
polici
provid
intern
author
person
conduct
anim
experi
qualiti
manag
system
certif
uni
en
iso
reg
nih
guid
care
use
laboratori
anim
edit
eu
direct
guidelin
eec
council
direct
statement
complianc
assur
public
health
servic
ph
polici
human
care
use
laboratori
anim
recent
review
expir
septemb
anim
welfar
assur
anim
bred
maintain
irccsistituto
di
ricerch
farmacologich
mario
negri
milan
standard
condit
temperatur
rel
humid
light
schedul
food
water
ad
libitum
transgen
mice
express
copi
mutant
human
substitut
origin
obtain
jackson
laboratori
maintain
genet
background
harlan
itali
srl
bresso
milan
itali
crossbreed
mice
mice
gener
mice
homogen
background
gener
marino
et
al
biochem
analys
femal
mice
deepli
anesthet
ketamin
hydrochlorid
imalgen
mgkg
alcyon
italia
spa
medetomidin
hydrochlorid
domitor
mgkg
alcyon
italia
spa
intraperiton
inject
euthan
decapit
symptom
onset
mice
week
age
mice
week
age
correspond
agematch
nontransgen
mice
use
control
peripher
blood
mononuclear
cell
isol
peripher
venou
blood
human
subject
essenti
previous
describ
nardo
et
al
briefli
sampl
blood
collect
edta
precoat
tube
bd
vacutain
pbmc
isol
edta
blood
ficollhypaqu
ficollplaquetm
plu
ge
healthcar
densiti
gradient
centrifug
g
min
mononuclear
cell
collect
interfac
wash
three
time
rpmi
medium
euroclon
platelet
elimin
addit
wash
centrifug
g
min
pbmc
store
pellet
pbmc
mice
isol
blood
sampl
intracardiac
punctur
collect
edta
precoat
vial
bd
vacutain
pbmc
isol
edtablood
lympholit
lympholytemamm
cedarlan
densiti
gradient
centrifug
g
min
mononuclear
cell
harvest
interfac
wash
g
min
rpmi
euroclon
supplement
mm
edta
store
pellet
analysi
human
mous
pbmc
lyse
mm
trishcl
ph
sd
supplement
proteas
inhibitor
sigma
boil
min
centrifug
g
min
supernat
analyz
western
dot
blot
analys
protein
quantifi
bca
protein
assay
pierc
spinal
cord
flush
vertebr
column
section
cervic
thorac
lumbar
segment
sampl
immedi
frozen
dryic
store
analysi
lumbar
spinal
cord
homogen
sonic
boil
sd
protein
homogen
boil
min
centrifug
g
min
supernat
analyz
western
dot
blot
analys
protein
quantifi
bca
protein
assay
pierc
peripher
blood
mononuclear
cell
protein
prepar
dige
analysi
follow
four
pool
earli
al
earli
control
late
al
late
control
methanolprecipit
overnight
protein
dissolv
mm
trishcl
ph
urea
thiourea
chap
wv
cydyelabel
accord
manufactur
instruct
ge
healthcar
minor
modif
briefli
pool
label
pmol
dye
min
ice
dark
exclud
preferenti
label
dye
sampl
also
revers
label
intern
standard
aliquot
pool
mix
label
dye
label
sampl
resuspend
destreak
solutiontm
ge
healthcar
ipg
buffer
ph
nl
vv
ge
healthcar
load
cmipg
strip
pi
rang
ge
healthcar
isoelectrofocus
done
ipgphor
apparatu
ge
healthcar
follow
protocol
vhr
v
vhr
v
vhr
v
vhr
linear
gradient
v
vhr
v
vhr
linear
gradient
v
vhr
v
sdspage
done
use
precast
trishcl
polyacrylamid
sd
gel
biorad
eight
gel
run
four
experiment
group
gel
contain
two
experiment
group
one
plu
intern
standard
gel
imag
captur
laser
scanner
molecular
imag
fx
biorad
imag
analysi
done
progenesi
spot
softwar
nonlinear
dynam
spot
normal
volum
standard
intern
standard
spot
normal
volum
valu
spot
group
express
mean
analys
valu
earli
late
al
normal
mean
valu
earli
late
control
respect
differenti
spot
consid
fold
chang
normal
late
al
normal
earli
al
differenti
protein
spot
locat
excis
gel
exquesttm
spot
cutter
biorad
spot
process
geldigest
modifi
trypsin
bovin
pancrea
roch
identifi
mass
spectrometri
ms
previous
describ
nardo
et
al
peptid
mass
fingerprint
tandem
msm
done
maldi
toftof
mass
spectromet
appli
biosystem
mass
spectra
intern
calibr
trypsin
autolysi
fragment
five
abund
precursor
ion
exclus
mass
list
ion
human
keratin
trypsin
select
msm
analysi
combin
ms
msm
data
submit
gp
explor
softwar
appli
biosystem
mascot
databas
search
engin
version
matrix
scienc
search
follow
paramet
uniprotswissprot
databas
homo
sapien
protein
sequenc
deposit
fix
modif
possibl
modif
carboamidomethyl
cystein
oxid
methionin
miss
trypsin
cleavag
mass
toler
da
peptid
mass
da
msm
fragment
ion
mass
protein
regard
identifi
mascot
protein
score
base
combin
ms
msm
data
signific
threshold
databas
pappin
et
al
identifi
protein
classifi
basi
gene
ontolog
go
annot
provid
mi
et
al
panther
overrepresent
test
perform
list
identifi
differenti
protein
whole
homo
sapien
refer
list
list
protein
extract
publish
work
proteom
lymphocytesmonocyt
verhoeckx
et
al
rosengren
et
al
xie
et
al
azkargorta
et
al
han
et
al
huang
et
al
ramirezboo
et
al
salonen
et
al
zada
et
al
henrich
et
al
lai
et
al
rakkola
et
al
skopel
et
al
vergara
et
al
panther
goslim
biolog
process
goslim
molecular
function
use
annot
data
set
version
releas
dot
blot
use
valid
studi
verif
antibodi
detect
specif
band
wb
supplementari
figur
protein
directli
load
onto
nitrocellulos
transblot
transfer
biorad
membran
deposit
sampl
membran
vacuum
filtrat
describ
previous
nardo
et
al
intern
standard
pool
sampl
analysi
healthi
control
patient
deposit
triplic
dot
blot
membran
block
wv
bsa
sigma
vv
tween
trisbuff
salin
ph
incub
primari
antibodi
peroxidaseconjug
secondari
antibodi
santa
cruz
biotechnolog
inc
blot
develop
luminatatm
fort
western
chemiluminesc
hrp
substrat
millipor
chemidoc
xr
system
biorad
densitometri
done
progenesi
softwar
nonlinear
dynam
immunoreact
differ
protein
normal
ponceau
red
stain
fluka
intern
standard
membran
immunoreact
valu
protein
analyz
earli
late
al
normal
mean
valu
earli
late
control
respect
statist
analysi
protein
express
two
group
done
student
ttest
use
prism
softwar
graphpad
san
diego
ca
usa
version
figur
schemat
show
strategi
use
identifi
valid
phenotyp
protein
biomark
al
pbmc
discoveri
phase
pbmc
al
patient
year
age
earli
al
ea
year
age
late
al
diagnosi
match
earli
late
control
analyz
dige
analysi
done
pool
sampl
four
experiment
group
tabl
spot
volum
valu
earli
late
al
normal
mean
valu
earli
late
control
respect
spot
consid
differenti
fold
chang
normal
late
alsnorm
earli
al
total
differenti
spot
detect
figur
spot
uniqu
protein
identifi
ms
candid
protein
biomark
tabl
protein
identifi
multipl
spot
differ
pi
mw
fragment
posttransl
modifi
isoform
protein
supplementari
tabl
group
differenti
protein
basi
recogn
function
go
annot
tabl
overrepresent
test
perform
list
differenti
protein
homo
sapien
refer
list
indic
isomeras
activ
associ
ppia
among
significantli
enrich
p
fold
molecular
function
protein
fold
respons
stress
among
significantli
enrich
p
fold
biolog
process
identifi
overrepresent
test
perform
also
refer
list
lymphocytemonocyt
protein
identifi
proteom
studi
indic
respons
stress
one
significantli
enrich
p
fold
biolog
process
suggest
protein
associ
molecular
function
biolog
process
tabl
ppia
attract
candid
phenotyp
biomark
valid
larger
wellcharacter
cohort
patient
earli
late
diseas
onset
valid
studi
analyz
total
protein
level
candid
phenotyp
biomark
ppia
dot
blot
analysi
pbmc
sampl
independ
set
al
patient
n
n
earli
al
n
late
al
match
control
n
n
earli
control
n
late
control
tabl
immunoreact
valu
protein
earli
late
al
patient
normal
mean
valu
earli
late
control
respect
similarli
proteom
analysi
found
ppia
significantli
lower
earli
al
late
al
therefor
consid
phenotyp
biomark
figur
e
chang
figur
moreov
ppia
similarli
regul
decreas
level
earli
al
compar
earli
control
opposit
tendenc
late
al
supplementari
figur
e
suggest
earli
al
patient
defect
respons
stress
pathway
valid
analysi
measur
anoth
chaperon
protein
differenti
analysi
upregul
pbmc
cohort
al
patient
mean
age
onset
year
previous
report
work
laboratori
nardo
et
al
found
could
distinguish
earli
late
al
figur
upregul
late
al
compar
control
supplementari
figur
confirm
total
protein
level
pbmc
underscor
diseas
figur
fact
higher
earli
late
al
compar
control
could
discrimin
earli
al
late
al
figur
note
assay
total
protein
level
compris
fulllength
fragment
form
supplementari
figur
experiment
set
analysi
strength
limit
major
strength
popul
base
enrol
patient
newli
diagnos
al
patient
fairli
repres
sampl
incid
al
popul
major
limit
small
sampl
size
analysi
may
thu
underpow
differ
achiev
statist
signific
adjust
data
multipl
comparison
thu
exclud
associ
chanc
find
howev
due
exploratori
natur
analysi
deliber
decid
use
bonferroni
correct
multipl
test
also
analyz
total
protein
level
candid
phenotyp
biomark
ppia
pbmc
two
mous
model
mice
correspond
nontransgen
control
dot
blot
analysi
mice
despit
equal
express
differ
diseas
phenotyp
differ
genet
background
marino
et
al
particular
mice
symptom
onset
week
age
respect
thu
repres
mous
model
earli
late
diseas
onset
similarli
human
sampl
immunoreact
valu
protein
earli
late
mous
model
normal
mean
valu
correspond
nontransgen
control
found
ppia
significantli
lower
earli
mice
late
mice
much
human
sampl
figur
b
signific
lower
level
two
protein
earli
mice
compar
nontransgen
control
supplementari
figur
b
similar
behavior
reach
statist
signific
figur
supplementari
figur
instead
significantli
higher
earli
mice
late
mice
figur
contrast
human
sampl
increas
level
earli
mice
compar
control
supplementari
figur
significantli
differ
late
earli
mice
much
human
sampl
figur
significantli
lower
late
mice
compar
control
supplementari
figur
final
significantli
differ
earli
late
mice
human
sampl
figur
differ
compar
correspond
nontransgen
control
contrast
human
sampl
supplementari
figur
total
protein
level
ppia
also
measur
lumbar
spinal
cord
homogen
earli
late
mice
diseas
onset
rel
agematch
nontransgen
control
dot
blot
analysi
figur
supplementari
figur
ppia
significantli
lower
earli
mice
late
mice
figur
e
similarli
regul
pbmc
isol
patient
supplementari
figur
indic
also
earli
mice
defect
respons
stress
pathway
alreadi
report
nardo
et
al
marino
et
al
differ
two
condit
human
sampl
figur
f
data
confirm
previou
work
differ
total
solubl
found
mice
respect
ntg
litterm
two
mous
strain
marino
et
al
conclus
observ
similar
regul
protein
pbmc
patient
pbmc
spinal
cord
mice
tabl
molecular
determin
al
heterogen
still
poorli
understood
anticip
delay
onset
diseas
may
caus
variou
combin
intrins
exogen
factor
converg
common
pathogen
pathway
underli
differ
suscept
al
eventu
lead
differ
prognosi
report
identif
protein
biomark
pbmc
discrimin
al
patient
earli
diseas
onset
late
diseas
onset
identifi
phenotyp
biomark
common
high
express
cn
import
role
protein
fold
foldas
andor
classic
molecular
chaperon
upregul
varieti
stressor
particip
differ
level
differ
way
mainten
proteostasi
whose
deficit
shown
gener
protein
misfold
aggreg
facilit
develop
sever
neurodegen
diseas
includ
al
ruegsegg
saxena
phenotyp
biomark
ppia
polyclon
antipeptidylprolyl
cistran
isomeras
ubiquit
express
highest
express
neuron
motor
neuron
lauranzano
et
al
peptidylprolyl
cistran
isomeras
foldas
acceler
ratelimit
step
along
fold
pathway
also
act
classic
molecular
chaperon
fischer
et
al
freskgard
et
al
origin
identifi
candid
protein
biomark
pbmc
al
patient
classic
diseas
onset
upregul
also
associ
diseas
progress
nardo
et
al
next
found
mutant
substrat
ppia
lauranzano
et
al
fact
absenc
ppia
increas
level
mutant
recov
aggreg
isol
spinal
cord
mice
also
anticip
onset
acceler
diseas
progress
one
abund
conserv
cytosol
heat
shock
protein
respons
correct
fold
number
newli
synthes
protein
refold
misfold
protein
associ
neurodegen
diseas
includ
basso
et
al
daturp
et
al
carlomagno
et
al
schirmer
et
al
accordingli
found
entrap
aggreg
isol
spinal
cord
mice
alreadi
presymptomat
stage
diseas
spinal
cord
tissu
sporad
al
patient
basso
et
al
major
er
chaperon
key
regul
unfold
protein
respons
disturb
er
homeostasi
common
featur
al
defect
er
chaperon
caus
motor
dysfunct
experiment
model
al
atkin
et
al
saxena
et
al
woehlbier
et
al
loss
one
copi
cofactor
anticip
diseas
onset
reduc
life
span
mous
model
de
l
etang
et
al
howev
precis
role
al
remain
determin
alzheim
diseas
studi
vitro
indic
may
part
defens
mechan
cell
inhibit
gener
peptid
yang
et
al
hoshino
et
al
multifunct
stress
respons
protein
strong
homogen
express
cn
region
bader
et
al
mutat
caus
earli
onset
autosom
recess
parkinson
diseas
bonifati
et
al
chaperon
alpha
synuclein
shown
protect
oxid
stress
upregul
shendelman
et
al
zhou
et
al
batelli
et
al
mous
model
increas
oxidizedinact
form
found
brain
tissu
knock
led
acceler
diseas
cours
shorten
surviv
time
lev
et
al
interestingli
found
ppia
present
lower
level
pbmc
patient
earli
onset
diseas
similar
behavior
pbmc
spinal
cord
earli
onset
mous
model
defect
protein
qualiti
control
previous
observ
marino
et
al
protein
patient
pbmc
mous
sampl
less
upregul
earli
al
late
al
ppia
evid
alreadi
presymptomat
stage
diseas
solubl
fraction
mous
spinal
cord
marino
et
al
base
differ
earli
lateonset
diseas
sole
genet
yet
unknown
case
mous
model
exogen
factor
exclud
patient
exampl
report
exposur
certain
toxin
lead
downregul
yang
et
al
namba
et
al
data
suggest
failur
respons
stress
reduc
abil
upregul
protect
protein
may
increas
suscept
al
agreement
fact
vulner
motor
neuron
high
threshold
induct
protect
heat
shock
respons
higher
sensit
er
stress
batulan
et
al
saxena
et
al
protein
signatur
compris
panel
protein
involv
proteostasi
may
underlin
subset
patient
suscept
diseas
may
help
stratifi
patient
target
al
clinic
trial
observ
strengthen
notion
proteostasi
mainten
system
autophagi
er
central
issu
al
therapeut
approach
aim
boost
protein
qualiti
control
system
might
promis
therapeut
strategi
arimoclomol
small
molecul
act
coinduc
heat
shock
respons
prolong
activ
upregul
number
protein
shown
effect
sever
experiment
model
motor
neuron
degener
includ
mous
kalmar
et
al
phase
ii
clinic
trial
al
patient
shown
drug
safe
well
toler
cudkowicz
et
al
investig
phaseiiiii
clinic
trial
posit
famili
al
patient
clinicaltrialsgov
identifi
colchicin
fdaapprov
drug
identifi
highthroughput
screen
enhanc
express
key
player
protein
qualiti
control
system
demonstr
facilit
remov
aggreg
autophagi
crippa
et
al
final
work
confirm
pbmc
valuabl
clinic
sampl
sinc
reflect
trait
diseas
observ
central
nervou
system
total
protein
level
pbmc
discrimin
al
patient
healthi
control
observ
previou
work
use
assay
nardo
et
al
also
confirm
experiment
set
mous
strain
examin
use
studi
diseas
suscept
test
novel
therapeut
approach
aim
address
diseas
heterogen
studi
carri
accord
gcp
recommend
written
inform
consent
subject
subject
gave
written
inform
consent
accord
declar
helsinki
protocol
approv
ethic
committe
particip
institut
procedur
involv
anim
care
conduct
conform
follow
law
regul
polici
govern
care
use
laboratori
anim
italian
govern
law
dlg
authoris
issu
march
ministri
health
mario
negri
institut
regul
polici
provid
intern
author
person
conduct
anim
experi
qualiti
manag
system
certif
uni
en
iso
reg
nih
guid
care
use
laboratori
anim
edit
eu
direct
guidelin
eec
council
direct
statement
complianc
assur
public
health
servic
ph
polici
human
care
use
laboratori
anim
recent
review
expir
septemb
anim
welfar
assur
studi
concept
design
eb
cb
vb
acquisit
analysi
interpret
data
author
draft
manuscript
vb
critic
revis
manuscript
eb
cb
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
